Specialized Research

KPV

Also known as: Lys-Pro-Val

Molecular Identifiers

Molecular Formula

C11H12O3

PubChem CID

13294447

Overview

Anti-inflammatory tripeptide derived from α-MSH (amino acids 11-13). Research in gut health. Can be administered orally or subcutaneously.

Sequence (1 letter): KPV
Extended notation: Lys-Pro-Val

Half-life

~30-60 minutes

Administration Route

Subcutaneous, oral, or topical

Category

Specialized Research

Mechanism of Action

  • Inhibition of the NF-κB pathway
  • Potent anti-inflammatory effect
  • Modulation of pro-inflammatory cytokines
  • Intestinal barrier protection

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 500-1000 mcg per injection
Frequency 1-2 times daily
Timing Any time of day
Duration 4-8 weeks

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Pain at injection site (rare)
  • Mild skin irritation (topical)

Presentations & Preparation

Vials of KPV found in the research market:

5 mg10 mg15 mg20 mg

Reconstitution

  • Diluent: Bacteriostatic water
  • Volume: 2 ml per vial
  • Inject the diluent slowly against the vial wall
  • Gently swirl until fully dissolved
  • Never shake

Storage

  • Lyophilized: Refrigerated 2-8°C
  • Reconstituted: Refrigerated 2-8°C (up to 30 days)
  • Protect from direct light
  • Do not freeze after reconstitution
Reconstitution Calculator

Scientific Studies

Published studies on KPV.

2008 · Gastroenterology

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D
2008 · Inflamm Bowel Dis

Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T

Related Peptides

Aviptadil

50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol

B7-33

100-500 mcg per injection (subcutaneous) · Once daily

Bronchogen

5-10 mg per day via subcutaneous injection · Once daily

Cardiogen

5-10 mg per day subcutaneously · Once daily

Chonluten

5-10 mg per day subcutaneously · Once daily

Crystagen

5-10 mg per day via subcutaneous injection · Once daily